- Red Light Holland (TRIP) notches certificate of analysis for psilocybin truffles
- The analysis was done by Crest Laboratories for the truffles that were grown in the Netherlands and imported to Canada
- The company has also chosen child-proof packaging for its micro-dosing capsules
- The capsules are intended to be distributed across Australasia by NUBU Pharmaceuticals
- Shares of Red Light Holland are up 11.11 per cent to C$0.10 as of 10:48 a.m. EDT
Red Light Holland (TRIP) has received a certificate of analysis for its psilocybin truffles.
The company said the analysis was done by Crest Laboratories for its truffles that were grown in the Netherlands and then imported to Canada under its Health Canada license.
“We are very hopeful that our prestigious partnerships with CCrest and NUBU Pharmaceuticals will bring about an excellent natural psilocybin microdosing product that has the potential of helping many people,” Todd Shapiro, CEO of Red Light Holland, said in a press release. “We will continue to carefully yet aggressively seek legal opportunities to increase responsible access to natural psilocybin around the world.”
Red Light Holland has also chosen child-proof packaging for its micro-dosing capsules. The capsules will be distributed across Australasia by NUBU Pharmaceuticals, subject to approval from Health Canada for exporting purposes.
“This is a great first step towards getting the Microdosing capsules distributed in Australasia,” Mark Dye, CEO of NUBU, said in a statement.
Shares of Red Light Holland (TRIP) are up 11.11 per cent to C$0.10 as of 10:48 a.m. EDT.